期刊文献+

维那利酮对犬实验性心力衰竭的影响 被引量:3

Effect of Chinese--made Vesnarinone on Experimental Heart Failure of Dog
下载PDF
导出
摘要 用戊巴比妥钠诱发犬急性心力衰竭,经股静脉注射本院研制的维那利酮3mg,继之静脉滴注每分钟0.1mg/kg,共30分钟,研究其血流动力学。结果,给药后,心衰竭犬的心输出量与左室内压最大变化速率均显著增加,并呈剂量依赖性。停药后30分钟,二者仍有明显变化。实验中,未发现血压、心率的变化,表明维那利酮正性肌力作用较强,且具有相对选择性。 Intravenous drip of sodiumpentobarbital 6 mg/kg per min inducedobvious heart failure of anesthetic dogs(n=11) followed by an infusion of 0.25mg/kgper min to maintain the heart failure state.The Chinese-made vesnarinone 3 mg/kgwas injected, followed by an infusion of0.1mg/kg per min, or the solvent in thesame volume, for 30 min. Vesnarinone in-creased significantly and instantly the car-diac output and left ventricular maximum+dp/dt, which almost recovered to normalat the end of the infusion and also signifi-cantly increased 30 min after administra-tion. The positive inotropic effect of vesna-rinone was not accompanied by an increasein the heart rate and the blood pressure.The results of our experiment reveal thatthe Chinese-made vesnarinone has a po-tent and relatively selective positive actionon heart failure of dogs.
出处 《华西医科大学学报》 CAS CSCD 1992年第2期178-180,共3页 Journal of West China University of Medical Sciences
基金 国家"七.五"攻关课题
关键词 维那利酮 心力衰竭 正性肌力药 Vesnarinone Heart failure Hemodynamics Positive inotropic agent
  • 相关文献

参考文献2

二级参考文献4

共引文献1

同被引文献15

  • 1张尊仪,杨正菀,韩五成.一种新型强心药—维司力农的药理与临床研究概况[J].中国临床药理学杂志,1993,9(4):226-230. 被引量:2
  • 2韩五成,秦韵,张尊仪,周素珍,杨正菀.国产新型强心药维司力农正性肌力作用的研究─—离体试验[J].华西医科大学学报,1994,25(3):316-320. 被引量:5
  • 3徐鸣夏,邓大为,秦韵,张尊仪,杨正菀.3,4-二甲氧基苯甲酰哌嗪衍生物的合成及其正性肌力作用初探[J].华西医科大学学报,1995,26(3):283-286. 被引量:3
  • 4张玉,李红宇,蓝庭剑,曾晓荣.维那利酮对培养鸡胚心室肌细胞L-型钙通道电流的影响[J].华西医科大学学报,1995,26(4):403-407. 被引量:3
  • 5Shigetake Sasayama MD. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure[J] 1990,Cardiovascular Drugs and Therapy(2):419~425
  • 6Spencer H. Kubo,Thomas S. Rector,John E. Strobeck,Jay N. Cohn. OPC-8212 in the treatment of congestive heart failure: Results of a pilot study[J] 1988,Cardiovascular Drugs and Therapy(5):653~660
  • 7Michitoshi Inoue MD,Masatsugu Hori,Hisakazu Yasuda,Tamotsu Takishima,Tsuneaki Sugimoto,Shigetake Sasayama,Tsunetaro Sakurai,Hiroshi Nonogi,Kazuhisa Kodama,Reizo Kusukawa,Motoomi Nakamura,Chuichi Kawai. A multicenter study of a new inotropic agent, piperanometozine (opc-8212) in congestive heart failure: Clinical improvement during short-term treatment[J] 1987,Cardiovascular Drugs and Therapy(2):169~175
  • 8Michitoshi Inoue,Bong-Ha Kim,Masatsugu Hori,Yutaka Tsuneoka,Noboru Matsubara,Takenobu Kamada,Kazuhisa Kodama,Masashi Naka,Shinsuke Nanto,Yorihiko Higashino. Oral OPC-8212 for the treatment of congestive heart failure: Hemodynamic improvement and increased exercise capacity[J] 1986,Heart and Vessels(3):166~171
  • 9Shigetake Sasayama,Michitoshi Inoue,Hidetsugu Asanoi,Kazuhisa Kodama,Masatsugu Hori,Tsunetaro Sakurai,Chuichi Kawai. Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure[J] 1986,Heart and Vessels(1):23~28
  • 10Shigetake Sasayama MD. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure[J] 1990,Cardiovascular Drugs and Therapy(2):419~425

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部